



**JANUARY  
23, 2021**

5:45 pm – 6:45 pm CET

## TOTALITY OF EVIDENCE ON RENAL BENEFITS IN CRM TRIALS – FOCUS ON SGLT2 INHIBITORS

Chairs: **Stefan D. Anker**, Berlin, Germany / **Milton Packer**, Dallas, TX, USA

Panelists: **George L. Bakris**, Chicago, IL, USA / **Gerasimos Filippatos**, Athens, Greece

- **Welcome and introduction**  
Stefan D. Anker, Berlin, Germany
- **Renal benefits of SGLT2 inhibitors in diabetes CV outcome trials**  
Katherine Tuttle, Seattle, WA, USA
- **Renal benefits of SGLT2 inhibitors in CKD trials**  
David C. Wheeler, London, UK
- **EMPA-KIDNEY: rationale, design, and status**  
Will Herrington, Oxford, UK
- **Interactive panel discussion**  
All faculty
- **Renal benefits of SGLT2 inhibitors in HF trials**  
Faiez Zannad, Nancy, France
- **On calculating slopes and assessing renal endpoints**  
Javed Butler, Jackson, MS, USA
- **Interactive panel discussion**  
All faculty
- **Conclusion**  
Milton Packer, Dallas, TX, USA

e-SPACE  
Cardio-Renal-Metabolic  
Global web-Conference 